Paper Details

  1. Home
  2. Paper Details

Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program.

Author: AuroraSheena K, BinderWilliam J, BlumenfeldAndrew, DodickDavid W, SilbersteinStephen D, TurkelCatherine C

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Chronic migraine (CM) is a common and disabling condition. OnabotulinumtoxinA, a medication that blocks pain-signaling substances, has been studied as a preventative treatment for various headaches, including CM. Initially, injections were given at fixed locations, but the approach evolved to include additional specific sites based on individual pain locations and tenderness. The PREEMPT injection paradigm, which combines fixed and personalized injection sites, has been shown to be safe, well-tolerated, and effective in clinical trials and is the recommended approach for managing CM.
Paper Details　
Original Abstract of the Article :
Chronic migraine (CM) is a prevalent and disabling neurological disorder. Few prophylactic treatments for CM have been investigated. OnabotulinumtoxinA, which inhibits the release of nociceptive mediators, such as glutamate, substance P, and calcitonin gene-related peptide, has been evaluated in ran...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/j.1526-4610.2010.01766.x

データ提供：米国国立医学図書館（NLM）

OnabotulinumtoxinA Injection for Chronic Migraine: A Promising Treatment Paradigm

Navigating the vast desert of chronic migraine research, we stumble upon this intriguing study that delves into the use of onabotulinumtoxinA injections as a potential treatment. It's a bit like finding an oasis in the middle of a scorching desert! The researchers utilized a sophisticated approach, involving a combination of fixed and follow-the-pain injection sites. This method, called the PREEMPT paradigm, was designed to pinpoint the specific areas causing the most discomfort. Their findings, like a shimmering mirage, suggest that this treatment is safe, well-tolerated, and effective in relieving chronic migraine symptoms.

The PREEMPT Paradigm: Targeting Pain with Precision

The PREEMPT paradigm, developed through a series of rigorous clinical trials, aims to personalize the treatment approach for each patient. It's like having a customized map to navigate the migraine desert, ensuring that the treatment effectively reaches the source of the pain. The results indicate that this tailored approach, which considers the individual's pain patterns, is a more effective way of treating chronic migraine than a one-size-fits-all approach.

Chronic Migraine Relief: A Ray of Hope in the Desert

This study brings a glimmer of hope for those enduring the relentless torment of chronic migraines. It suggests that onabotulinumtoxinA, when administered using the PREEMPT paradigm, could potentially offer significant relief from migraine symptoms. It's like finding a cool spring in the desert, offering much-needed respite from the heat and discomfort.

Dr. Camel's Conclusion

This research offers a promising new avenue for treating chronic migraine, emphasizing the importance of personalized treatment approaches. The PREEMPT paradigm, like a well-traveled desert path, provides a clear roadmap for delivering onabotulinumtoxinA injections with precision, potentially leading to lasting relief for many.

Date :
  1. Date Completed 2013-05-09
  2. Date Revised 2022-03-10
Further Info :

Pubmed ID

20958294

DOI: Digital Object Identifier

10.1111/j.1526-4610.2010.01766.x

Related Literature

Article Analysis
・Effective treatment of migraine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.